Uses generative AI to design novel protein-based medicines across multiple disease areas.
Uses generative AI to design novel protein-based medicines across multiple disease areas.
Has no approved medicine yet; income so far has come from upfront and milestone payments under partnerships such as those with Novartis and Amgen, with the rest funded by investors. Its approach is to design proteins by computer and test them in the lab, feeding results back into the models.
Moat: narrow (data, IP / patents, process know-how). Generative AI platform for de novo protein design, backed by Flagship Pioneering and a Novartis partnership.
Headquarters: Somerville, Massachusetts, US · Founded: 2018 · Employees: 312
Size Generate Biomedicines (GENB) is a United States Health Care company (Biotechnology) with a market value of $1.34B, the 2048th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.38 on 18 Nov 2026.
Performance Over six months the shares fell 20.3%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 55.9% over the last twelve months (peer median +14.4%); the operating margin is -737.0% (peer median -16.5%).
Valuation It trades at 31.7× enterprise value to sales against a peer median of 8.4× (8th most expensive of 19).
Short interest Short interest is 7.1% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $31.9M | $20.5M |
| Revenue growth | — | +56% | — |
| Gross profit | n/a | $18.7M | $5.11M |
| EBITDA | n/a | -$222M | -$182M |
| Net income | n/a | -$203M | -$174M |
| Free cash flow | n/a | -$204M | -$121M |
| Capital expenditure | n/a | $3.51M | $3.45M |
| Total debt | $75.3M | $68.5M | $77.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Generate Biomedicines GENB | $1.34B | -20% | +56% | -737% | 31.7× | n/a |
| Absci ABSI | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a |
| Recursion Pharmaceuticals RXRX | $1.76B | -5% | +56% | -725% | 18.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GENB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.5% | -14.8% | 6th lowest of 21 |
| 6-month return | -20.3% | -20.3% | 10th highest of 20 |
| Distance from 52-week high | -54.2% | -46.5% | 6th lowest of 21 |
| Revenue growth (TTM) | +55.9% | +14.4% | 6th highest of 19 |
| Operating margin | -737.0% | -16.5% | 7th lowest of 20 |
| EV / Sales | 31.7× | 8.4× | 8th most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | 164.8× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.36B | -23% | +36% | -4% | 6.8× | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 2.4× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | 170.1× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 9.0× | 33.2% | -13.1% |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 3.5× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 2.2× | 6.6% | -7.0% |